ENDRA Life Sciences Inc.

As of June 30, 2026, ENDRA Life Sciences Inc. carries a market capitalization of 7.99M, placing it among publicly traded companies globally. Its enterprise value stands at 6.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ENDRA Life Sciences Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, ENDRA Life Sciences Inc. has 1.50M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, ENDRA Life Sciences Inc. maintains a current ratio of 7.10, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, ENDRA Life Sciences Inc. posted a negative return on equity (ROE) of -152.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -110.08, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 13.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, ENDRA Life Sciences Inc.'s stock has declined approximately 9.30% over the past 52 weeks. The 50-day moving average sits at 5.40, while the 200-day moving average is 4.80.

Over the twelve months ended June 30, 2026, ENDRA Life Sciences Inc. generated - - in revenue and converted that into -5.92M in net income, yielding earnings per share of -4.37. EBITDA reached -6.49M, while operating income came in at -6.65M.

As of June 30, 2026, ENDRA Life Sciences Inc. holds 1.74M in cash and equivalents against 429,274.00 in total debt, resulting in a net debt position of -1.74M. Total book value stands at 6.31M, with working capital of 4.80M providing operational flexibility.

ENDRA Life Sciences Inc. produced -4.82M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -18,670.00 in capital expenditures, free cash flow totaled -4.84M - equivalent to -4.55 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -67.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -111.17, meaning ENDRA Life Sciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ENDRA Life Sciences Inc.'s most recent stock split took place on November 7, 2024 with a 35:1 split ratio.

As of June 30, 2026, ENDRA Life Sciences Inc. has an Altman Z-Score of -25.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.